ESPNFollow live: Rays extend lead after another defensive miscue by YankeesESPN DeportesEN VIVO: Rays recupera ventaja con ataque en la quintaThe Jerusalem PostBoard of Peace ‘not stepping back’ from Gaza plan ahead of Israeli elections - reportInquirerDefense team did not intend to threaten anyone – PoaPunchNigeria overtakes four nations in Africa investment ranking한겨레‘알래스카 LNG 추진계획’ 빠진 산업부 업무보고…국감서 “국익 최우선” 강조VarietySkydance to Fully Reorganize International; Kevin MacLellan Will Not Lead Key GroupZDF heuteAktuelle Pressemitteilungen des ZDFUOLApucarana aprova idade mínima de 16 anos para scooter, bikes e patinetes elétricosNew Straits TimesBahrain part ways with Talajic after Gulf Cup early exit3DNewsБывшие инженеры Groq подали в суд на правление из-за неправомерной сделки с Nvidia경향신문유류세 인하 5년…온실가스 400만t 감축 기회 놓쳤다
The Daily Newsstand · Free, Always
Tuesday, October 6, 2026

JW中外製薬「エンパガード、既存治療より血糖低下」

Translate

JW中外製薬は糖尿病治療薬「エンパガード」の臨床第3相試験で、既存の2剤併用療法より血糖値を下げる効果を確認した。同社は今回の臨床結果を基に、エンパガードの処方拡大に乗り出す計画だ。JW中外製薬は6日、最近開かれた欧州糖尿病学会年次学術大会(EASD 2026)で、2型糖尿病治療薬エンパガードの臨床第3相試験結果を発表したと明らかにした。エンパガードはDPP-4阻害

Read the full article on 조선일보 →

KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.